Yasmin and venous thromboembolism: new case reports.
It is not yet known whether Yasmin involves a higher thrombotic risk compared with other contraceptives. We present a serie of eight new cases of women who developed thrombotic events early after starting on Yasmin who were sent to our Thrombosis and Hemostasis Unit for a thrombophilia work-up in the last five years. Only two of them were heterozygous carriers of the prothrombin G20210A mutation and three were obese while none of them were smoker. These new cases provide information about the characteristics of the thrombotic events and the concomitant risk factors, indicating that this pill may not be as safe as had been previously thought, and suggest that new studies regarding safety profile of Yasmin are required to explain the association with venous thrombotic events.
Haemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain.
María
M
López
Amparo
A
Vayá
M Luisa
ML
Martínez Triguero
M Teresa
MT
Contreras
José
J
Todolí
Alicia
A
Ricart
Begoña
B
Laiz
D000328:Adult; D000736:Androstenes / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D011516:Prothrombin / Q000235:genetics; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000139:chemically induced*; D055815:Young Adult
D000736:Androstenes; D003277:Contraceptives, Oral, Combined; C534342:drospirenone and ethinyl estradiol combination; D004997:Ethinyl Estradiol; D011516:Prothrombin